AtriCure（ATRC）株式概要
アトリキュア社は、心臓組織の外科的アブレーション、左心房付属器の排除、末梢神経のアブレーションによる痛みの一時的遮断のための機器の開発、製造、販売を米国、アジア太平洋地域、および海外の医療施設向けに行っています。 詳細
ATRC Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AtriCure, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$28.80 |
| 52週高値 | US$43.18 |
| 52週安値 | US$25.36 |
| ベータ | 1.26 |
| 1ヶ月の変化 | 1.80% |
| 3ヶ月変化 | -2.74% |
| 1年変化 | -9.72% |
| 3年間の変化 | -40.91% |
| 5年間の変化 | -63.92% |
| IPOからの変化 | 104.55% |
最新ニュース
分析記事 • 16h
AtriCure (ATRC) Stock Could Be 45.4% Undervalued As Growth Narrative Faces A Cash Flow Test
AtriCure (ATRC) is back on investor watchlists after recent trading left the stock around $28.80, inviting fresh scrutiny of its valuation against a backdrop of mixed short term and longer term returns. See our latest analysis for AtriCure. The recent 1 day share price return of 6.2% contrasts with weaker longer term performance, with the year to date share price return down 26.7% and the 5 year total shareholder return down 64.1%, suggesting recent momentum is rebuilding from a lower...
ナラティブの更新 • Jun 17
ATRC: Accelerated BoxX-NoAF Trial And Firmer P E Frame Will Support Repricing
Analysts have nudged their average AtriCure price target higher by $2, citing recent research that points to slightly stronger revenue and margin expectations, which in turn support a modestly lower discount rate and P/E assumption. Analyst Commentary Recent research on AtriCure points to a more constructive tone, with bullish analysts highlighting factors they see as supportive of the latest price target adjustments and valuation assumptions.ナラティブの更新 • Jun 03
ATRC: Raised Coverage And P E Outlook Will Support Bullish Repricing
Analysts have raised their AtriCure price target by $2, citing recent supportive research that points to a more constructive view on the stock and its long term assumptions around growth, margins, and future P/E levels. Analyst Commentary Recent research points to a more constructive stance on AtriCure, with bullish analysts emphasizing how current expectations for growth, margins, and future P/E levels could support the stock’s long term investment case.ナラティブの更新 • May 19
ATRC: Product Moat And Clinical Data Will Support Bullish Repricing
Analysts have trimmed their fair value estimate for AtriCure to $55 from $64, reflecting updated assumptions for slightly softer revenue growth, a modestly lower profit margin outlook, and a reduced future P/E multiple, even as recent research points to ongoing product progress and a still supportive view from several firms despite rising competitive concerns. Analyst Commentary Recent research on AtriCure highlights a split in views, with some firms flagging competitive threats and others pointing to ongoing execution in sales, earnings, and product development as support for current valuations.Recent updates
分析記事 • 16h
AtriCure (ATRC) Stock Could Be 45.4% Undervalued As Growth Narrative Faces A Cash Flow Test
AtriCure (ATRC) is back on investor watchlists after recent trading left the stock around $28.80, inviting fresh scrutiny of its valuation against a backdrop of mixed short term and longer term returns. See our latest analysis for AtriCure. The recent 1 day share price return of 6.2% contrasts with weaker longer term performance, with the year to date share price return down 26.7% and the 5 year total shareholder return down 64.1%, suggesting recent momentum is rebuilding from a lower...ナラティブの更新 • Jun 17
ATRC: Accelerated BoxX-NoAF Trial And Firmer P E Frame Will Support Repricing
Analysts have nudged their average AtriCure price target higher by $2, citing recent research that points to slightly stronger revenue and margin expectations, which in turn support a modestly lower discount rate and P/E assumption. Analyst Commentary Recent research on AtriCure points to a more constructive tone, with bullish analysts highlighting factors they see as supportive of the latest price target adjustments and valuation assumptions.ナラティブの更新 • Jun 03
ATRC: Raised Coverage And P E Outlook Will Support Bullish Repricing
Analysts have raised their AtriCure price target by $2, citing recent supportive research that points to a more constructive view on the stock and its long term assumptions around growth, margins, and future P/E levels. Analyst Commentary Recent research points to a more constructive stance on AtriCure, with bullish analysts emphasizing how current expectations for growth, margins, and future P/E levels could support the stock’s long term investment case.ナラティブの更新 • May 19
ATRC: Product Moat And Clinical Data Will Support Bullish Repricing
Analysts have trimmed their fair value estimate for AtriCure to $55 from $64, reflecting updated assumptions for slightly softer revenue growth, a modestly lower profit margin outlook, and a reduced future P/E multiple, even as recent research points to ongoing product progress and a still supportive view from several firms despite rising competitive concerns. Analyst Commentary Recent research on AtriCure highlights a split in views, with some firms flagging competitive threats and others pointing to ongoing execution in sales, earnings, and product development as support for current valuations.
ナラティブの更新 • May 01
ATRC: Clinical Strength And 2026 Profitability Are Expected To Offset New Competition
The updated analyst price target for AtriCure now reflects a modest valuation reset in the mid to high $50 range, as analysts weigh recent target cuts and rating downgrades against ongoing confidence in the company's product pipeline, clinical data strength, and prospects for durable revenue growth with improving profitability. Analyst Commentary Recent research has introduced a mix of optimism and caution around AtriCure, with bullish views on the product portfolio and clinical positioning sitting alongside fresh concerns about competition and long term growth durability.ナラティブの更新 • Apr 17
ATRC: Clinical Moat And 2026 Profitability Are Expected To Withstand New Entrant
Narrative Update on AtriCure The updated analyst price target for AtriCure has edged down by about $0.23, reflecting a slightly higher discount rate and lower expected future P/E. Analysts are weighing new competitive risks against continued confidence in the company’s product pipeline, clinical data, and profitability progress.ナラティブの更新 • Apr 02
ATRC: 2026 Guidance And Clinical Moat Are Expected To Outlast New Competition
Analysts have modestly reduced the AtriCure price target by $1.31 to $36.41. This reflects both lower published Street targets in response to emerging competition and continued confidence in revenue growth, margins, and the company’s clinical and product positioning.ナラティブの更新 • Mar 19
ATRC: 2026 Guidance And Clinical Moat Will Confront Emerging Competition
Analysts have trimmed AtriCure's average price target by a few dollars to around the mid $50s. This reflects a mix of confidence in recent sales and EPS outperformance and product progress, tempered by concerns about emerging competition in left atrial appendage closure products and long term growth risks.ナラティブの更新 • Mar 04
ATRC: 2026 Guidance And New Dual Energy Platform Will Shape Upside
Analysts have adjusted their outlook on AtriCure, with our updated fair value estimate moving from $36.00 to about $37.72. This change reflects a mix of lower Street price targets, concerns about emerging competition, and continued confidence in the company’s product progress, clinical data, and profitability trajectory.ナラティブの更新 • Feb 18
ATRC: JPMorgan Downgrade And 2026 Profit Outlook Will Shape Risk Balance
Analysts have revised their AtriCure price target from $40.00 to $36.00, citing updated assumptions around discount rates, revenue growth, profit margins, and elevated future P/E expectations in light of recent research, including the JPMorgan downgrade. Analyst Commentary Recent commentary points to a more cautious stance on AtriCure, with the revised US$36.00 target reflecting what bearish analysts see as a need to factor in higher risk around execution, profitability, and future growth expectations.
ナラティブの更新 • Feb 04
ATRC: Dual Energy Platform Trial Progress Will Support Long Term Upside Potential
Analysts have adjusted their price targets on AtriCure, reflecting updated assumptions around discount rates, revenue growth, profit margins and a revised future P/E of 134.36x. Collectively, these factors support a fair value estimate of about $52.78 per share.ナラティブの更新 • Jan 21
ATRC: Future Trial Progress Will Drive Confidence In Long Term Outlook
AtriCure's updated analyst price target has increased from US$50.00 to about US$52.78. Analysts cite adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the key drivers of this change.ナラティブの更新 • Jan 06
ATRC: Dual Energy Ablation Breakthrough Will Drive Bullish Repricing
Analysts have maintained their price target on AtriCure at US$64.00, citing updated assumptions for slightly higher revenue growth, wider profit margins, a modestly higher discount rate, and a lower future P/E multiple as key inputs to their valuation work. What's in the News AtriCure announced successful first in human procedures using its dual energy platform that combines Pulsed Field Ablation with Advanced Radiofrequency Ablation, performed at Victorian Heart Hospital in Australia under Monash Health HREC approval (Key Developments).ナラティブの更新 • Dec 15
ATRC: Dual Energy Platform And Noaf Trial Will Drive Bullish Repricing
Analysts have raised their price target on AtriCure by approximately 7 percent to 64 dollars per share, reflecting greater confidence in the company’s improving profit margin outlook and more favorable long term valuation assumptions, despite a slightly higher discount rate. What's in the News AtriCure reported successful first in human procedures with its dual energy ablation platform that combines Pulsed Field Ablation with Advanced Radiofrequency Ablation, achieving box lesion creation and pulmonary vein plus posterior wall isolation in under 60 seconds in the first two patients (company announcement).分析記事 • Dec 11
AtriCure, Inc.'s (NASDAQ:ATRC) 29% Share Price Surge Not Quite Adding Up
AtriCure, Inc. ( NASDAQ:ATRC ) shares have had a really impressive month, gaining 29% after a shaky period beforehand...分析記事 • Nov 01
AtriCure, Inc. (NASDAQ:ATRC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
AtriCure, Inc. ( NASDAQ:ATRC ) defied analyst predictions to release its quarterly results, which were ahead of market...分析記事 • Aug 01
AtriCure, Inc. (NASDAQ:ATRC) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
AtriCure, Inc. ( NASDAQ:ATRC ) investors will be delighted, with the company turning in some strong numbers with its...分析記事 • Jul 08
AtriCure (NASDAQ:ATRC) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Jun 26
AtriCure: Profits And Operating Leverage Are Needed Here
Summary AtriCure has had impressive and sound growth over the past decade. The company has continued to post losses, even though relative losses are coming down. The combination of double-digit sales growth and a 3 times sales multiple looks compelling, yet further margin gains are required to drive appeal here. Read the full article on Seeking Alpha分析記事 • May 01
AtriCure, Inc. (NASDAQ:ATRC) Screens Well But There Might Be A Catch
It's not a stretch to say that AtriCure, Inc.'s ( NASDAQ:ATRC ) price-to-sales (or "P/S") ratio of 3.1x seems quite...分析記事 • Apr 04
Is AtriCure (NASDAQ:ATRC) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
新しいナラティブ • Mar 22
cryoSPHERE+ And EnCompass Clamp Launches Will Accelerate Global Adoption
New product launches and international expansion, especially in Europe and China, are key drivers for AtriCure's projected revenue growth and market leadership.分析記事 • Jan 22
Revenues Tell The Story For AtriCure, Inc. (NASDAQ:ATRC) As Its Stock Soars 29%
AtriCure, Inc. ( NASDAQ:ATRC ) shares have continued their recent momentum with a 29% gain in the last month alone...分析記事 • Jan 15
Calculating The Fair Value Of AtriCure, Inc. (NASDAQ:ATRC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, AtriCure fair value estimate is US$35.69 With US$34.69 share...分析記事 • Dec 24
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Nov 06
A Piece Of The Puzzle Missing From AtriCure, Inc.'s (NASDAQ:ATRC) 28% Share Price Climb
Despite an already strong run, AtriCure, Inc. ( NASDAQ:ATRC ) shares have been powering on, with a gain of 28% in the...分析記事 • Nov 01
US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results
AtriCure, Inc. ( NASDAQ:ATRC ) defied analyst predictions to release its third-quarter results, which were ahead of...分析記事 • Oct 31
Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?
AtriCure, Inc. ( NASDAQ:ATRC ), is not the largest company out there, but it saw a significant share price rise of 71...分析記事 • Oct 02
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 43% Above Its Share Price
Key Insights AtriCure's estimated fair value is US$39.81 based on 2 Stage Free Cash Flow to Equity Current share price...分析記事 • Sep 06
Further Upside For AtriCure, Inc. (NASDAQ:ATRC) Shares Could Introduce Price Risks After 29% Bounce
AtriCure, Inc. ( NASDAQ:ATRC ) shareholders would be excited to see that the share price has had a great month, posting...分析記事 • Aug 02
Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report
There's been a notable change in appetite for AtriCure, Inc. ( NASDAQ:ATRC ) shares in the week since its...Seeking Alpha • Jul 25
AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care
Summary AtriCure, Inc. is a market leader in surgical solutions for atrial fibrillation, LAA management, and post-operative pain management, serving 2,000 hospitals globally. AtriCure's latest project involves expanding into the European market with innovative products, facing potential regulatory delays and market acceptance challenges. Despite facing competition from major players like Johnson & Johnson and Medtronic, AtriCure's strong revenue growth and innovative product lineup position it for continued success in the market. Read the full article on Seeking Alpha分析記事 • Jul 18
AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward
AtriCure, Inc. ( NASDAQ:ATRC ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...分析記事 • May 30
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, AtriCure fair value estimate is US$40.72 AtriCure's US$21.61...分析記事 • Apr 04
Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump
AtriCure, Inc. ( NASDAQ:ATRC ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • Mar 14
Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Jan 21
Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues
When close to half the companies in the Medical Equipment industry in the United States have price-to-sales ratios (or...分析記事 • Nov 29
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Sep 27
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price
Key Insights AtriCure's estimated fair value is US$84.48 based on 2 Stage Free Cash Flow to Equity Current share price...分析記事 • Aug 02
Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...株主還元
| ATRC | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | 2.9% | -1.1% | 1.4% |
| 1Y | -9.7% | -20.7% | 25.7% |
業界別リターン: ATRC過去 1 年間で-20.7 % の収益を上げたUS Medical Equipment業界を上回りました。
リターン対市場: ATRCは、過去 1 年間で25.7 % のリターンを上げたUS市場を下回りました。
価格変動
| ATRC volatility | |
|---|---|
| ATRC Average Weekly Movement | 5.8% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: ATRC 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: ATRCの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2000 | 1,350 | Mike Carrel | www.atricure.com |
アトリキュア社は、心臓組織の外科的アブレーション、左心房付属器の排除、末梢神経をアブレーションして痛みを一時的に遮断する機器の開発、製造、販売を米国、アジア太平洋地域、および海外の医療施設向けに行っている。単回使用の使い捨て高周波製品であるIsolator Synergy Ablation Systemクランプ、不整脈治療用の単回使用の使い捨て高周波製品である多機能ペンとリニアアブレーション装置、様々な長さのリニアアブレーションを可能にするcryoICE Cryoablation System、症候性、薬剤抵抗性、長期持続性心房細動の治療に使用される単回使用の使い捨て装置であるEPi-Sense Systemsを提供している。また、cryoSPHEREプローブも提供している。これは、胸郭にある標的の鎖骨間末梢神経に低温エネルギーを加えることにより、一時的な疼痛緩和を提供するものである。AtriClipシステムは、単回使用の使い捨てアプライヤーと結合した移植可能な装置である；また、EPi-SenseカテーテルのアクセスをサポートするSubtle Cannulaも販売している。さらに、同社は様々な再利用可能な心臓手術器具を販売している。同社は、独立系販売代理店および直販担当者を通じて製品のマーケティングおよび販売を行っている。同社は2000年に法人化され、オハイオ州メイソンに本社を置いている。
AtriCure, Inc. 基礎のまとめ
| ATRC 基礎統計学 | |
|---|---|
| 時価総額 | US$1.46b |
| 収益（TTM） | -US$4.59m |
| 売上高(TTM) | US$552.16m |
2.6x
P/Sレシオ-317.5x
PER（株価収益率ATRC は割高か？
公正価値と評価分析を参照収益と収入
| ATRC 損益計算書（TTM） | |
|---|---|
| 収益 | US$552.16m |
| 売上原価 | US$134.70m |
| 売上総利益 | US$417.46m |
| その他の費用 | US$422.06m |
| 収益 | -US$4.59m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.091 |
| グロス・マージン | 75.61% |
| 純利益率 | -0.83% |
| 有利子負債／自己資本比率 | 12.4% |
ATRC の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/22 07:35 |
| 終値 | 2026/06/18 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
AtriCure, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18
| アナリスト | 機関 |
|---|---|
| Charley Jones | Barrington Research Associates, Inc. |
| Marie Thibault | BTIG |
| Michael Gorman | BTIG |